Results 251 to 260 of about 8,158 (292)
Some of the next articles are maybe not open access.
Journal of Intensive Care Medicine, 2015
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the known incretin hormones in humans, released predominantly from the enteroendocrine K and L cells within the gut. Their secretion is regulated by a complex of integrated mechanisms involving direct contact for the activation of different chemo-sensors on the ...
Tongzhi, Wu +2 more
openaire +4 more sources
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the known incretin hormones in humans, released predominantly from the enteroendocrine K and L cells within the gut. Their secretion is regulated by a complex of integrated mechanisms involving direct contact for the activation of different chemo-sensors on the ...
Tongzhi, Wu +2 more
openaire +4 more sources
The role of incretins and incretin-based drugs in autoimmune diseases
International Immunopharmacology, 2021Incretin hormones, including glucagon-like peptide (GLP)-1, GLP-2 and glucose-dependent insulinotropic polypeptide (GIP), are gastrointestinal peptides secreted from enteroendocrine cells. These hormones play significant roles in many physiological processes via binding to G-protein coupled receptors (GPCRs) on different organs and tissues; one of them
Shabnam Radbakhsh +3 more
openaire +2 more sources
Modulation of Diabetes by Natural Products and Medicinal Plants via Incretins [PDF]
Planta Medica, 2019 Incretins are metabolic hormones released after a meal that increase insulin secretion from pancreatic β-cells. The two main incretins are the intestinal peptides glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
José-Luis Rios +2 more
exaly +2 more sources
Mayo Clinic Proceedings, 1988
A greater plasma concentration of insulin after isoglycemic enteral than after parenteral administration of glucose is called the incretin effect. The primary mediator of this effect, gastric inhibitory polypeptide, may not account for the complete manifestation of this phenomenon.
L T, Shuster +4 more
openaire +2 more sources
A greater plasma concentration of insulin after isoglycemic enteral than after parenteral administration of glucose is called the incretin effect. The primary mediator of this effect, gastric inhibitory polypeptide, may not account for the complete manifestation of this phenomenon.
L T, Shuster +4 more
openaire +2 more sources
Scandinavian Journal of Clinical and Laboratory Investigation, 2001
Incretin hormones are insulinotropic hormones from the intestinal mucosa, which after being released in response to ingestion of a meal, enhance insulin secretion in excess of that elicited by the absorbed nutrients (glucose. amino acids etc) themselves.
Holst, J.J., Orskov, C.
openaire +2 more sources
Incretin hormones are insulinotropic hormones from the intestinal mucosa, which after being released in response to ingestion of a meal, enhance insulin secretion in excess of that elicited by the absorbed nutrients (glucose. amino acids etc) themselves.
Holst, J.J., Orskov, C.
openaire +2 more sources
Incretin Pharmacology: A Review of the Incretin Effect and Current Incretin-Based Therapies
Cardiovascular & Hematological Agents in Medicinal Chemistry, 2012Given the demonstrated importance of the incretin effect on the prandial insulin response, augmentation of the incretin effect in people with type 2 diabetes is an important pharmacological approach to glycemic management. In recent years, the use of incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, has increased ...
openaire +2 more sources
GLUCOREGULATORY ACTIONS OF INCRETINS/ANTI-INCRETINS
2023Diabetes mellitus (DM) is a chronic debilitating and non-communicable disease characterized by chronic hyperglycemia and resulting from a defect in insulin secretion, insulin action, or both. Apart from these, defective actions of the gastrointestinal (GI) incretin hormones: glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinotropic ...
openaire +1 more source
Incretins and risk of neoplasia
BMJ, 2013An association exists but causality has not yet been proved Incretin based treatment for type 2 diabetes improves hyperglycaemia without causing weight gain and is increasingly being used worldwide. Concerns have been raised about long term safety, as reported by Cohen,1 especially the risk of pancreatitis and pancreatic cancers—both adenocarcinoma ...
Thorvardur R, Halfdanarson +1 more
openaire +2 more sources
Hormone and Metabolic Research, 2004
Incretins are hormones released by nutrients from the GI tract. They amplify glucose-induced insulin release. By raising circulating incretin levels, oral glucose provokes a higher insulin response than that resulting from intravenous glucose. The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon ...
S, Efendic, N, Portwood
openaire +2 more sources
Incretins are hormones released by nutrients from the GI tract. They amplify glucose-induced insulin release. By raising circulating incretin levels, oral glucose provokes a higher insulin response than that resulting from intravenous glucose. The two most important incretin hormones are glucose-dependent insulinotropic polypeptide (GIP) and glucagon ...
S, Efendic, N, Portwood
openaire +2 more sources
Cardiovascular benefits of incretins
BMJ, 2013Cohen and colleagues make no mention of the evidence that treatment of type 2 diabetes with increasingly larger doses of sulfonylureas and insulin is not without serious risk from hypoglycaemia, weight gain, and possibly increased cardiovascular risk.1 A balanced account of this is needed in any review of incretins.
Anthony H, Barnett, Paul, O'Hare
openaire +2 more sources